AbbVie Inc. is trading 3% up at $223.65, extending its recent multi-day rebound from last week’s pullback despite a lack of fresh company-specific headlines.
- The move follows strong Q1 2026 results and a supportive Wall Street rating backdrop that continues to drive positive sentiment.
- Shares are benefiting from a risk-on rotation into value and defensive healthcare names as the broader market remains mixed.